T cell epitope mapping of secukinumab and ixekizumab in healthy donors

References

• Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490–10. doi:https://doi.org/10.4049/jimmunol.1100123.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–11. doi:https://doi.org/10.1038/sj.jid.5701213.
   PubMed Web of Science ®Google Scholar
• Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26. doi:https://doi.org/10.1038/jid.2012.194.
   PubMed Web of Science ®Google Scholar
• Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MB. Overrepresentation of IL-17a and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108.
   PubMed Web of Science ®Google Scholar
• Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24. doi:https://doi.org/10.1111/bjd.2009.160.issue-2.
   PubMed Web of Science ®Google Scholar
• Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, Santamaria M. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86(2):435–43. doi:https://doi.org/10.1189/JLB.0109046.
   PubMed Web of Science ®Google Scholar
• Garcia-Montoya L, Marzo-Ortega H. The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Ther Adv Musculoskelet Dis. 2018;10(9):169–80. doi:https://doi.org/10.1177/1759720X18787766.
   PubMed Web of Science ®Google Scholar
• Wendling D, Verhoeven F, Prati C. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2019;19(1):55–64. doi:https://doi.org/10.1080/14712598.2019.1554053.
   PubMed Web of Science ®Google Scholar
• Sekhon S, Jeon C, Nakamura M, Yan D, Afifi L, Bhutani T, Levin E. Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Psoriasis (Auckl). 2017;7:65–72. doi:https://doi.org/10.2147/PTT.S129792.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.
   PubMedGoogle Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (feature). Br J Dermatol. 2015;172(2):484–93. doi:https://doi.org/10.1111/bjd.2015.172.issue-2.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. doi:https://doi.org/10.1056/NEJMoa1314258.
   PubMed Web of Science ®Google Scholar
• Paul C, JP L, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C; group Js. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: A randomized, controlled trial (juncture). J Eur Acad Dermatol Venereol. 2015;29(6):1082–90. doi:https://doi.org/10.1007/s13555-018-0220-y.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, et al. Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39. doi:https://doi.org/10.1056/NEJMoa1412679.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (sculpture). J Am Acad Dermatol. 2015;73(1):27–36 e21. doi:https://doi.org/10.1016/j.jaad.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11. doi:https://doi.org/10.1111/bjd.12070.
   PubMed Web of Science ®Google Scholar
• Balato A, Scala E, Balato N, Caiazzo G, Di Caprio R, Monfrecola G, Raimondo A, Lembo S, Ayala F. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017;17(11):1363–74. doi:https://doi.org/10.1080/14712598.2017.1363884.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewe R, Conaghan PG, Gottlieb AB, et al. Secukinumab, a human anti-interleukin-17a monoclonal antibody, in patients with psoriatic arthritis (future 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2015;386(9999):1137–46. doi:https://doi.org/10.1016/S0140-6736(15)61134-5.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs. 2017;31(4):299–316. doi:https://doi.org/10.1007/s40259-017-0231-8.
   PubMed Web of Science ®Google Scholar
• Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G. Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176(3):752–58. doi:https://doi.org/10.1111/bjd.14965.
   PubMed Web of Science ®Google Scholar
• Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G. Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019. doi:https://doi.org/10.1111/jdv.15637.
   Google Scholar
• Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr., Shete A, Bruin G. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2019. doi:https://doi.org/10.3899/jrheum.190116.
   Google Scholar
• Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, Barmettler B, Nelson J, Bina H, Huang L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17a. J Inflamm Res. 2016;9:39–50. doi:https://doi.org/10.2147/JIR.S100940.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewe R, et al. Ixekizumab, an interleukin-17a antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (coast-v): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet (London, England). 2018;392(10163):2441–51. doi:https://doi.org/10.1016/S0140-6736(18)31946-9.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P. Safety and efficacy of ixekizumab in patients with psa and previous inadequate response to tnf inhibitors: week 52 results from spirit-p2. Rheumatology (Oxford). 2018;57(11):2001–11. doi:https://doi.org/10.1093/rheumatology/key182.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56. doi:https://doi.org/10.1056/NEJMoa1512711.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, Ball S, Mallbris L, Gonzalez P, Fernandez-Penas P, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the uncover-3 study. J Am Acad Dermatol. 2018;79(5):824–830 e822. doi:https://doi.org/10.1016/j.jaad.2018.05.032.
   PubMed Web of Science ®Google Scholar
• Eli lilly and co. 2016 Taltz (ixekizumab) [package insert]. [accessed 06th aug 2019] https://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2016/125521s000lbl.Pdf.
   Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MABS. 2016;8(3):536–50. doi:https://doi.org/10.1080/19420862.2015.1136761.
   PubMed Web of Science ®Google Scholar
• Spindeldreher S, Maillere B, Correia E, Tenon M, Karle A, Jarvis P, Kolbinger F. Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther (Heidelb). 2018;8:57–68.
   PubMed Web of Science ®Google Scholar
• Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. Faseb J. 2011;25(6):2040–48. doi:https://doi.org/10.1096/fj.10-173872.
   PubMed Web of Science ®Google Scholar
• Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood. 2010;116(22):4542–45. doi:https://doi.org/10.1182/blood-2010-04-280875.
   PubMed Web of Science ®Google Scholar
• Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, Pallardy M, Carbonnel F, Spindeldreher S, Mariette X, et al. Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors. Front Immunol. 2017;8:500. doi:https://doi.org/10.3389/fimmu.2017.00500.
   PubMed Web of Science ®Google Scholar
• Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med. 2011;208(12):2375–83. doi:https://doi.org/10.1084/jem.20111502.
   PubMed Web of Science ®Google Scholar
• Honegger A, Pluckthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol. 2001;309(3):657–70. doi:https://doi.org/10.1006/jmbi.2001.4662.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MABS. 2010;2(3):256–65. doi:https://doi.org/10.4161/mabs.2.3.11641.
   PubMed Web of Science ®Google Scholar
• Lefranc MP. IMGT, the international immunogenetics database. Nucleic Acids Res. 2001;29(1):207–09. doi:https://doi.org/10.1093/nar/29.1.207.
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, Carillon E, Duvergey H, Houles A, Paysan-Lafosse T, et al. IMGT(r), the international immunogenetics information system(r) 25 years on. Nucleic Acids Res. 2015;43(Database issue):D413–422. doi:https://doi.org/10.1093/nar/gku1056.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol. 2007;44(8):1986–98. doi:https://doi.org/10.1016/j.molimm.2006.09.029.
   PubMed Web of Science ®Google Scholar